CXCL16 and neoplasm: For this reason, the use of CXCL16-neutralizing antibody [87] or an antagonist of the CXCR6 receptor [188] inhibits tumor progression in in vitro experiments, in particular in pancreatic ductal adenocarcinoma [87] and hepatocellular carcinoma [188].